Dynamics of Immune Checkpoints, Immune System, and BCG in the Treatment of Superficial Bladder Cancer
暂无分享,去创建一个
Bilgen Kaymakamzade | Evren Hincal | Farouk Tijjani Saad | B. Kaymakamzade | F. Saad | E. Hıncal | F. T. Saad
[1] J. Chaskalovic,et al. A mathematical model of combined bacillus Calmette-Guerin (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer. , 2011, Journal of theoretical biology.
[2] Yu Yao,et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. , 2015, Trends in molecular medicine.
[3] D. Lamm,et al. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. , 1980, The Journal of urology.
[4] K. Starkov,et al. Dynamical properties and tumor clearance conditions for a nine-dimensional model of bladder cancer immunotherapy. , 2016, Mathematical biosciences and engineering : MBE.
[5] D. Kirschner,et al. Modeling immunotherapy of the tumor – immune interaction , 1998, Journal of mathematical biology.
[6] A. Böhle,et al. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. , 2003, The Journal of urology.
[7] X. Zang,et al. The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion , 2011, Journal of biomedicine & biotechnology.
[8] H. Niu,et al. Effect of TLR4 and B7-H1 on immune escape of urothelial bladder cancer and its clinical significance. , 2014, Asian Pacific journal of cancer prevention : APJCP.
[9] J. Wolchok,et al. Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Subhas Khajanchi,et al. A Mathematical Model to Elucidate Brain Tumor Abrogation by Immunotherapy with T11 Target Structure , 2014, PloS one.
[12] Yoshimasa Tanaka,et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[13] M. Glickman,et al. The mechanism of action of BCG therapy for bladder cancer—a current perspective , 2014, Nature Reviews Urology.
[14] M. Newton,et al. Bladder Cancer Immunotherapy: BCG and Beyond , 2012, Advances in urology.
[15] R. Kapoor,et al. Bacillus Calmette-Guérin in the management of superficial bladder cancer , 2008, Indian journal of urology : IJU : journal of the Urological Society of India.
[16] A. Yoshimura,et al. TGF-β function in immune suppression. , 2010, Current topics in microbiology and immunology.
[17] Svetlana Bunimovich-Mendrazitsky,et al. Mathematical Model of BCG Immunotherapy in Superficial Bladder Cancer , 2007, Bulletin of mathematical biology.
[18] S. Holmäng,et al. Bacillus Calmette‐Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression , 2004, BJU international.
[19] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[20] S. Halachmi,et al. Improving Bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer by adding interleukin 2 (IL-2): a mathematical model. , 2016, Mathematical medicine and biology : a journal of the IMA.
[21] H. Nishiyama,et al. Bacillus Calmette–Guerin (BCG) immunotherapy for bladder cancer: Current understanding and perspectives on engineered BCG vaccine , 2013, Cancer science.
[22] N. Vasdev,et al. Immunotherapy for bladder cancer , 2015, Research and Reports in Urology.
[23] G. Freeman,et al. PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.
[24] G. Freeman,et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.
[25] F. Paillard. Immunosuppression mediated by tumor cells: a challenge for immunotherapeutic approaches. , 2000, Human gene therapy.
[26] Svetlana Bunimovich-Mendrazitsky,et al. Mathematical Model of Pulsed Immunotherapy for Superficial Bladder Cancer , 2008, Bulletin of mathematical biology.
[27] L. Xerri,et al. PD-1 is a novel regulator of human B-cell activation. , 2013, International Immunology.